The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...
AbbVie will pay up to $2.2 billion to develop Danish drugmaker Gubra’s obesity drug. AI takes center stage at HIMSS ...
AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...
AbbVie is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of its May 2025 meeting, fostering investor attention. Despite reporting a Q4 net ...
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...
The booming weight loss drug market has gained a new potential competitor. AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug ...
AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback